230 related articles for article (PubMed ID: 30282449)
1. Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.
Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):886-900. PubMed ID: 30282449
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
Wang S; Oh DY; Leventaki V; Drakos E; Zhang R; Sahin AA; Resetkova E; Edgerton ME; Wu W; Claret FX
Cancer Lett; 2019 Nov; 465():12-23. PubMed ID: 31473252
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
4. CSN5/JAB1 suppresses the WNT inhibitor DKK1 in colorectal cancer cells.
Jumpertz S; Hennes T; Asare Y; Schütz AK; Bernhagen J
Cell Signal; 2017 Jun; 34():38-46. PubMed ID: 28229932
[TBL] [Abstract][Full Text] [Related]
5. Jab1-siRNA Induces Cell Growth Inhibition and Cell Cycle Arrest in Gall Bladder Cancer Cells via Targeting Jab1 Signalosome.
Pandey P; Siddiqui MH; Behari A; Kapoor VK; Mishra K; Sayyed U; Tiwari RK; Shekh R; Bajpai P
Anticancer Agents Med Chem; 2019; 19(16):2019-2033. PubMed ID: 31345154
[TBL] [Abstract][Full Text] [Related]
6. Jab1 promotes glioma cell proliferation by regulating Siah1/β-catenin pathway.
Zhu Y; Qiu Z; Zhang X; Qian F; Wang B; Wang L; Shi H; Yu R
J Neurooncol; 2017 Jan; 131(1):31-39. PubMed ID: 27640199
[TBL] [Abstract][Full Text] [Related]
7. S100A7, Jab1, and p27
Granata M; Skarmoutsou E; Gangemi P; Mazzarino MC; D'Amico F
J Cell Biochem; 2019 Mar; 120(3):3384-3392. PubMed ID: 30203426
[TBL] [Abstract][Full Text] [Related]
8. The crucial p53-dependent oncogenic role of JAB1 in osteosarcoma in vivo.
Samsa WE; Mamidi MK; Bashur LA; Elliott R; Miron A; Chen Y; Lee B; Greenfield EM; Chan R; Danielpour D; Zhou G
Oncogene; 2020 Jun; 39(23):4581-4591. PubMed ID: 32390003
[TBL] [Abstract][Full Text] [Related]
9. Gfer inhibits Jab1-mediated degradation of p27kip1 to restrict proliferation of hematopoietic stem cells.
Teng EC; Todd LR; Ribar TJ; Lento W; Dimascio L; Means AR; Sankar U
Mol Biol Cell; 2011 Apr; 22(8):1312-20. PubMed ID: 21346186
[TBL] [Abstract][Full Text] [Related]
10. Jab1/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51.
Liu G; Yu M; Wu B; Guo S; Huang X; Zhou F; Claret FX; Pan Y
Cell Signal; 2019 Jan; 53():39-48. PubMed ID: 30244171
[TBL] [Abstract][Full Text] [Related]
11. The novel Jab1 inhibitor CSN5i-3 suppresses cell proliferation and induces apoptosis in human breast cancer cells.
Xiao H; Claret FX; Shen Q
Neoplasma; 2019 May; 66(3):481-486. PubMed ID: 30868895
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways.
Pan Y; Zhang Q; Atsaves V; Yang H; Claret FX
Oncogene; 2013 May; 32(22):2756-66. PubMed ID: 22797071
[TBL] [Abstract][Full Text] [Related]
13. Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression.
Pan Y; Wang S; Su B; Zhou F; Zhang R; Xu T; Zhang R; Leventaki V; Drakos E; Liu W; Claret FX
Oncogene; 2017 Feb; 36(8):1069-1079. PubMed ID: 27524414
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of JAB1 promotes malignant behavior and predicts poor prognosis in esophageal squamous cell carcinoma.
Shen Q; Shang B; Jiang B; Wang Y; Wang Z; Chen G
Thorac Cancer; 2020 Apr; 11(4):973-982. PubMed ID: 32064781
[TBL] [Abstract][Full Text] [Related]
15. Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma.
Kouvaraki MA; Korapati AL; Rassidakis GZ; Tian L; Zhang Q; Chiao P; Ho L; Evans DB; Claret FX
Cancer Res; 2006 Sep; 66(17):8581-9. PubMed ID: 16951171
[TBL] [Abstract][Full Text] [Related]
16. Cytoplasmic localization of Jab1 and p27 Kip1 might be associated with invasiveness of papillary thyroid carcinoma.
Ahn J; Hong SA; Lee SE; Kim J; Oh YS; Park SJ; Chung YJ
Endocr J; 2009; 56(5):707-13. PubMed ID: 19461157
[TBL] [Abstract][Full Text] [Related]
17. JAB1/COPS5 is a putative oncogene that controls critical oncoproteins deregulated in prostate cancer.
Danielpour D; Purighalla S; Wang E; Zmina PM; Sarkar A; Zhou G
Biochem Biophys Res Commun; 2019 Oct; 518(2):374-380. PubMed ID: 31434609
[TBL] [Abstract][Full Text] [Related]
18. Basic investigation on the development of molecular targeting therapy against cyclin-dependent kinase inhibitor p27Kip1 in head and neck cancer cells.
Supriatno ; Harada K; Yoshida H; Sato M
Int J Oncol; 2005 Sep; 27(3):627-35. PubMed ID: 16077910
[TBL] [Abstract][Full Text] [Related]
19. The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression.
Tomoda K; Kato JY; Tatsumi E; Takahashi T; Matsuo Y; Yoneda-Kato N
Blood; 2005 Jan; 105(2):775-83. PubMed ID: 15353483
[TBL] [Abstract][Full Text] [Related]
20. Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells.
Shackleford TJ; Zhang Q; Tian L; Vu TT; Korapati AL; Baumgartner AM; Le XF; Liao WS; Claret FX
Breast Cancer Res; 2011 Jun; 13(3):R65. PubMed ID: 21689417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
